RU2636032C2 - Применение антитела i-3859 для выявления и диагностики рака - Google Patents

Применение антитела i-3859 для выявления и диагностики рака Download PDF

Info

Publication number
RU2636032C2
RU2636032C2 RU2014103054A RU2014103054A RU2636032C2 RU 2636032 C2 RU2636032 C2 RU 2636032C2 RU 2014103054 A RU2014103054 A RU 2014103054A RU 2014103054 A RU2014103054 A RU 2014103054A RU 2636032 C2 RU2636032 C2 RU 2636032C2
Authority
RU
Russia
Prior art keywords
cxcr4
sequence
seq
cdr
antibody
Prior art date
Application number
RU2014103054A
Other languages
English (en)
Russian (ru)
Other versions
RU2014103054A (ru
Inventor
Кристин КЛИНГЕР-АМУР
Александра ЖУАННО
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2014103054A publication Critical patent/RU2014103054A/ru
Application granted granted Critical
Publication of RU2636032C2 publication Critical patent/RU2636032C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2014103054A 2011-07-29 2012-07-30 Применение антитела i-3859 для выявления и диагностики рака RU2636032C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
EP11306000.8 2011-07-29
US61/513,345 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (2)

Publication Number Publication Date
RU2014103054A RU2014103054A (ru) 2015-09-10
RU2636032C2 true RU2636032C2 (ru) 2017-11-17

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103054A RU2636032C2 (ru) 2011-07-29 2012-07-30 Применение антитела i-3859 для выявления и диагностики рака

Country Status (14)

Country Link
US (1) US20140170677A1 (enExample)
EP (1) EP2736926A1 (enExample)
JP (1) JP6138780B2 (enExample)
KR (1) KR20140047127A (enExample)
CN (1) CN103717620A (enExample)
AR (1) AR087363A1 (enExample)
AU (2) AU2012292116A1 (enExample)
BR (1) BR112014001979A2 (enExample)
CA (1) CA2842552A1 (enExample)
IL (1) IL230693A0 (enExample)
MX (1) MX2014001160A (enExample)
RU (1) RU2636032C2 (enExample)
WO (1) WO2013017562A1 (enExample)
ZA (1) ZA201400500B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208776A1 (ja) * 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
WO2017070582A1 (en) * 2015-10-23 2017-04-27 Novartis Ag Computer method and system for deriving cell-to-cell spatial proximities
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
JP2021502071A (ja) * 2017-11-07 2021-01-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんバイオマーカーおよびその使用方法
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EA010163B1 (ru) * 2003-05-02 2008-06-30 Полифор Аг СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156581T5 (es) * 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
EP1286684B1 (en) 2000-05-09 2004-04-28 The University Of British Columbia use of cxcr4 antagonists for treating autoimmune diseases and cancer
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
MX2009003306A (es) * 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010163B1 (ru) * 2003-05-02 2008-06-30 Полифор Аг СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
JP2014523920A (ja) 2014-09-18
AU2017204043A1 (en) 2017-07-06
RU2014103054A (ru) 2015-09-10
US20140170677A1 (en) 2014-06-19
CA2842552A1 (en) 2013-02-07
AR087363A1 (es) 2014-03-19
ZA201400500B (en) 2014-11-26
WO2013017562A1 (en) 2013-02-07
AU2012292116A1 (en) 2014-02-06
KR20140047127A (ko) 2014-04-21
IL230693A0 (en) 2014-03-31
MX2014001160A (es) 2014-07-14
BR112014001979A2 (pt) 2017-02-21
JP6138780B2 (ja) 2017-05-31
EP2736926A1 (en) 2014-06-04
CN103717620A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
RU2636032C2 (ru) Применение антитела i-3859 для выявления и диагностики рака
RU2636345C2 (ru) Новое антитело к cxcr4 и его применение для выявления и диагностики рака
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
TW201311726A (zh) 抗體ｉ－３８５９用於癌症偵測及診斷之用途
OA18453A (en) IGF-1R antibody and its use for the diagnosis of cancer
HK1243434B (zh) Igf-1r抗体及其诊断癌症的用途
HK1183311A (en) Novel antibody for the diagnosis and/or prognosis of cancer

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180731